Summary
The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric Research Equity Act (PREA). RACE Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This paper discusses the need for and the importance of pediatric research, the RACE Act, and how it applies to precision medicine.
Register to download
RACE Act Prompts More Pediatric Clinical Trials for Oncology Drug Developers
You may also be interested in:
Blog
Putting the “Patient Perspective” in Pediatric Patient Engagement
During PRA Health Sciences’ celebration of UNICEF’s World’s Children Day on November 20, experts from LSU-Shreveport, UNICEF, the Center for…
Blog
Ask the Experts: How Can We Ensure Pediatric Oncology is at the Forefront of Legislation?
LeAnn joined PRA in October 2018 as a Senior Project Manager, working primarily on oncology clinical trials. We sat down with her to hear her…
Blog
Including Children in COVID-19 Trials: Challenges and Opportunities
You may have heard the buzz surrounding a new severe inflammatory condition observed in children that seems to be connected with COVID-19 infection.…